Global Policy Forum
Overview
HTAi’s mission is to support and promote the development, communication, understanding and use of HTA around the world as a scientifically based means of promoting the introduction of effective innovations and the effective use of resources in health care.
The HTAi Global Policy Forum provides a unique opportunity for senior representatives from public and private sector organizations using HTA to support decisions or recommendations about product development and coverage to meet one another, members of the HTAi Board and invited international experts, for strategic discussions about the present state of HTA, its development and its implications for health care systems, industry, patients and other stakeholders. The aim of the Forum is to provide an environment where senior representatives can engage in strategic discussions informed by the perspectives of their different organizations without the constraints associated with discussions of specific products or organizational policies.
Membership in the HTAi Global Policy Forum is by application. From time to time (typically around April each year), HTAi issues calls for expressions of interest in joining the Global Policy Forum. Final decisions on membership are made by the HTAi Board of Directors on advice from the Global Policy Forum Organizing Committee.
Dates & Locations
- The Hague (23-25 January 2022)
- Virtual (Feb. 22, 24 & 26, 2021)
- New Orleans (26-28, January 2020)
- Barcelona (27-29 January 2019)
- Barcelona (28-30 January 2018)
- Barcelona (29-31 January 2017)
- San Francisco (January 31 – February 2, 2016)
For further reading, please visit our Papers and Articles page.
Policy Forum Members
- Abbott Vascular International BVBA
- AMGEN (Europe) GmbH
- AstraZeneca (UK) Ltd
- Boston Scientific Corporation
- Bristol-Myers Squibb
- Edwards Lifesciences
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline
- Johnson & Johnson
- Medtronic
- Merck & Co
- Merck KGaA
- Novartis Pharma AG
- Pfizer Limited
- Sanofi Genzyme
- BCBSA – Blue Cross Blue Shield Association (USA)
- CADTH – Canadian Agency for Drugs and Technologies in Health (Canada)
- CMTP – Center for Medical Technology Policy (USA)
- CONITEC – National Committee for Technology Incorporation (Brazil)
- HAS – French National Authority for Health (France)
- Healthcare Improvement Scotland (UK)
- HTAA – Health Technology Assessment Association (Russia)
- ICER – Institute for Clinical & Economic Review (USA)
- IQWiG – Institute for Quality and Efficiency in Health Care (Germany)
- Kaiser Permanente (USA)
- NECA – National Evidence-based Healthcare Collaborating Agency (South Korea)
- NICE – National Institute for Health and Care Excellence (UK)
- NIPHNO – Norwegian Institute of Public Health Norway (Norway)
- PBAC & MSAC Australia Government, Department of Health and Ageing (Australia)
- PCORI – Patient-Centered Outcomes Research Institute (USA)
- Swedish Council on HTA (SBU) and Swedish Dental and Pharmaceutical Benefits Agency (TLV) – joint membership (Sweden)
- ZINL – National Health Care Institute (Netherlands)
- AQuaS – Agency of Health Quality and Assessment of Catalonia (Spain)
- BC Cancer (Canada)
- IETS – Institute of Technological Evaluation in Health (Colombia)
Additional information
Questions?
Contact the HTAi Secretariat.